Generate Biomedicines, Inc. (GENB)
17.17
+0.05
(+0.29%)
USD |
NASDAQ |
Sep 18, 16:00
17.17
0.00 (0.00%)
After-Hours: 19:50
Generate Biomedicines Cash from Operations (Quarterly) : -57.94M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -57.94M |
| March 31, 2026 | -80.39M |
| Date | Value |
|---|---|
| June 30, 2025 | -48.75M |
| March 31, 2025 | -53.18M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Twist Bioscience Corp. | 1.115M |
| Intellia Therapeutics, Inc. | -83.11M |
| Prime Medicine, Inc. | -41.05M |
| Moderna, Inc. | -526.00M |
| Beam Therapeutics, Inc. | -66.10M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 33.31M |
| Cash from Financing (Quarterly) | -0.579M |
| Free Cash Flow | -245.88M |
| Free Cash Flow Per Share (Quarterly) | -0.459 |
| Free Cash Flow to Equity (Quarterly) | -55.94M |
| Free Cash Flow to Firm (Quarterly) | -58.72M |
| Free Cash Flow Yield | -17.76% |